|
| [January 10, 2013] |
 |
Research and Markets: Diagnostics Partnering Yearbook 2013
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/hd82qr/diagnostics)
has announced the addition of the "Diagnostics
Partnering Yearbook 2013" report to their offering.
The Diagnostics Partnering Yearbook 2013 report series provides
comprehensive understanding and unprecedented access to the partnering
deals and agreements entered into by the worlds leading healthcare
companies during 2012.
Using these reports, dealmakers will effectively and efficiently gain
insight into the partnering activities of the past year. The report
series allows you to view all the partnering and alliances deals
announced worldwide.
The initial chapters of this report provide an orientation of 2012's
dealmaking and business activities.
Chapter 1 provides an overview of the trends in dealmaking during 2012
covering trends by deal type, stage of development, technology type and
therapeutic indication.
Chapter 2 provides a review of the leading deals during 2012. Deals are
listed by headline value, signed by bigpharma and bigbiotech, and most
active bigpharma. Where the deal has an agreement contract published at
the SEC (News - Alert) a link provides online access to the contract.
/p>
Chapter 3 provides a comprehensive listing of the top 50 bigpharma
companies with a brief summary followed by a comprehensive listing of
2012 deals, as well as contract documents available in the public
domain. Each deal title links via Weblink to an online version of the
deal record and where available, the contract document, providing easy
access to each contract document on demand.
Chapter 4 provides a comprehensive directory of all partnering deals
announced during 2012.
The chapter is organized by company A-Z, stage of development at
signing, deal type (collaborative R&D, co-promotion, licensing etc),
therapy area and technology type. Each deal title links via Weblink to
an online version of the deal record and where available, the contract
document, providing easy access to each contract document on demand.
The report series also includes numerous tables and figures that
illustrate the trends and activities in bigpharma partnering and
dealmaking during 2012.
In conclusion, this report provides everything a prospective dealmaker
needs to know about partnering in the research, development and
commercialization of technologies and products during 2012.
Companies Mentioned
-
Abbott
-
Actavis
-
Actelion
-
Allergan
-
Amgen
-
Aspen Pharmacare
-
Astellas
-
AstraZeneca
-
Baxter International
-
Bayer
-
Biogen Idec
-
Boehringer Ingelheim
-
Bristol-Myers Squibb
-
Celgene
-
CSL
-
Daiichi Sankyo
-
Dainippon Sumitomo
-
Eisai
-
Eli Lilly
-
Endo Pharmaceuticals
-
Forest Laboratories
-
Galderma
-
Gilead Sciences
-
GlaxoSmithKline
-
Grifols
-
Hospira
-
Johnson & Johnson
-
Kyowa Hakko Kirin
-
Lundbeck
-
Menarini
-
Merck & Co
-
Merck KGaA
-
Mitsubishi (News - Alert) Tanabe
-
Novartis
-
Novo Nordisk
-
Otsuka
-
Pfizer
-
Purdue
-
Roche
-
Sanofi
-
Servier
-
Shionogi
-
Shire
-
Takeda
-
Teva
-
Valeant
-
Warner Chilcott
-
Watson
For more information visit http://www.researchandmarkets.com/research/hd82qr/diagnostics

[ Back To Technology News's Homepage ]
|